ストックスクリーナーアプリを入手
40.75
1.21%
-0.50
プレマーケット:
41.60
0.85
+2.09%
Crinetics Pharmaceuticals Inc (CRNX) 最新ニュース
Technical Reactions to CRNX Trends in Macro Strategies - Stock Traders Daily
[144] Crinetics Pharmaceuticals, Inc. SEC Filing - Stock Titan
The Bull Case For Crinetics Pharmaceuticals (CRNX) Could Change Following EU Nod For Oral Acromegaly Drug PALSONIFY - Yahoo Finance
Analysts estimate Crinetics Pharmaceuticals, Inc. (CRNX) to report a decline in earnings: What to look out for - MSN
Crinetics Pharmaceuticals (CRNX): Billionaire Tom Steyer Likes This Pharma Stock - Insider Monkey
Crinetics Pharmaceuticals Inc (HAM:6Z4) Valuation: Possible Value Trap, Think Twice - GuruFocus
Analysts Estimate Crinetics Pharmaceuticals, Inc. (CRNX) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance
Weekly Buzz: FDA Okays Saphnelo Pen, EC Clears Acromegaly Drug, SNGX Slumps, LGND Snaps Up XOMA - RTTNews
Crinetics Pharmaceuticals (CRNX) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Crinetics Pharmaceuticals Inc Stock Intrinsic Values | HAM:6Z4 - GuruFocus
Q3 2024 Crinetics Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Q2 2025 Crinetics Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Crinetics Pharmaceuticals Inc Stock Historical Valuations - GuruFocus
Q4 2025 Crinetics Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Q3 2025 Crinetics Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Q1 2025 Crinetics Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Crinetics Pharmaceuticals Inc Stock Warning Signs - GuruFocus
Crinetics Pharmaceuticals Inc (HAM:6Z4) Stock Earnings Transcripts - GuruFocus
Crinetics Pharmaceuticals Inc (HAM:6Z4)Valuation Measures & Financial Statistics - GuruFocus
Crinetics Pharmaceuticals Inc (HAM:6Z4) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Crinetics Pharmaceuticals Inc Stock Baskets - GuruFocus
Crinetics Pharmaceuticals Inc (HAM:6Z4) Stock News, Headlines & Updates - GuruFocus
Crinetics Pharmaceuticals Inc (HAM:6Z4) Stock HoldersInstitutional & Insider Ownership - GuruFocus
Who's Buying or Selling Crinetics Pharmaceuticals Inc (HAM:6Z4) Stock Today? - GuruFocus
Crinetics Pharmaceuticals Inc (HAM:6Z4) Stock Price, Trades & News - GuruFocus
Crinetics Pharmaceuticals Inc (HAM:6Z4) Stock Price & 30 Year Financial Data - GuruFocus
Crinetics Pharmaceuticals Inc Stock Operating Data - GuruFocus
Crinetics Pharmaceuticals Inc (HAM:6Z4) Dividend - GuruFocus
Vanguard Capital Management holds 5.19% of Crinetics (NASDAQ: CRNX) - Stock Titan
Crinetics (NASDAQ: CRNX) details 2026 meeting, board votes and auditor change - Stock Titan
Indivior, Liquidia, Crinetics top Quant pharma list as Merck scoops up Terns for $6.7B - MSN
Crinetics Pharmaceuticals Files Marketing Application for Acromegaly Drug in Brazil - HarianBasis.co
Crinetics Pharmaceuticals (CRNX) is One of the Best Biotech Stocks to Buy, Here is Why - Insider Monkey
Q1 Earnings Estimate for CRNX Issued By Lifesci Capital - MarketBeat
Pictet Asset Management Holding SA Has $72.63 Million Stock Holdings in Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
5 Best Biotech Stocks with Highest Upside Potential - Insider Monkey
CRNX Maintains Market Outperform Rating -- Price Target Raised t - GuruFocus
Crinetics Pharmaceuticals (NASDAQ:CRNX) Given New $97.00 Price Target at Citizens Jmp - MarketBeat
Citizens raises Crinetics stock price target on EU drug approval By Investing.com - Investing.com Canada
Crinetics receives EU approval for acromegaly drug Palsonify By Investing.com - Investing.com India
Crinetics (CRNX) Secures EU Approval for Palsonify in Acromegaly Treatment - GuruFocus
Crinetics receives EU approval for acromegaly drug Palsonify - Investing.com UK
Crinetics Pharmaceuticals Announces the European Commission Approval of PALSONIFY® (Paltusotine) for the Treatment of Acromegaly in Adults - The Manila Times
Crinetics Pharmaceuticals Announces the European Commission - GlobeNewswire
Impax Asset Management Group plc Buys Shares of 275,000 Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
A Look At Crinetics Pharmaceuticals (CRNX) Valuation After Mixed Recent Share Performance - Sahm
Trading the Move, Not the Narrative: (CRNX) Edition - Stock Traders Daily
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
CRNX Stock Price, Quote & Chart | CRINETICS PHARMACEUTICALS IN (NASDAQ:CRNX) - ChartMill
Neutrolis Appoints Caren Deardorf as Chief Business & Strategy Officer - GlobeNewswire Inc.
Crinetics (CRNX) Stock: Trading Guide (Range-Bound) 2026-04-15Stock Trading Network - Cổng thông tin điện tử tỉnh Tây Ninh
CRNX (NASDAQ: CRNX) files Rule 144: 20,900-share exercise, prior 10b5-1 sales - Stock Titan
Insider Sales: CRNX (NASDAQ: CRNX) 4,434-share option sale; Knight 95,074 prior shares - Stock Titan
(CRNX) Volatility Zones as Tactical Triggers - Stock Traders Daily
Fed Meeting: Is Crinetics Pharmaceuticals Inc stock a top performer YTD2026 Rallies & Free Real-Time Market Sentiment Alerts - baoquankhu1.vn
Crinetics Pharmaceuticals Signs Independent Consultant Agreement with Jeff Knight – 8-K Filing Details and XBRL Information - Minichart
Crinetics Pharma chief dev officer sells $3.4m in stock By Investing.com - Investing.com Canada
0.14%
0.48%
大文字化:
|
ボリューム (24 時間):